Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals

A Southwest Oncology Group pilot study

Charles W. Taylor, John Crowley, Stephen K. Williamson, Thomas P Miller, Sarah A. Taylor, T. G Shanker Giri, Ronald L. Stephens, Robert B Livingston

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

We designed an intensive, weekly treatment regimen for patients with small-cell lung cancer (SCLC) using six of the most active chemotherapeutic agents for this disease (doxorubicin [DOX], cyclophosphamide [CTX], vincristine [VCR], etoposide [VP-16], cisplatin [CDDP], and methotrexate [MTX]). The goal of this program was to gain rapid, repetitive exposure to multiple, active drugs. Treatment was administered weekly for a total of 16 weeks. Seventy-six SCLC patients (limited disease, 34; extensive disease, 42) were treated. The overall complete plus partial response rate was 82%. Complete response rates of 47% and 38% were observed in patients with limited (LD) and extensive disease (ED), respectively. The median survivals for patients with LD and ED were 16.6 and 11.4 months, respectively. Toxicities were tolerable and were primarily hematologic. Twenty-six patients had one or more transient life-threatening toxicities, but only one patient developed a fatal toxicity. Eighty-four percent of the patients received 80% or greater of the intended protocol dosages over the entire 16-week treatment period. We conclude that this intensive, short-duration treatment regimen is at least as good as other "standard" regimens, and we are encouraged by the complete response rate and median survival in patients with ED SCLC.

Original languageEnglish (US)
Pages (from-to)1811-1817
Number of pages7
JournalJournal of Clinical Oncology
Volume8
Issue number11
StatePublished - Nov 1990
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Etoposide
Therapeutics
Vincristine
Methotrexate
Doxorubicin
Cyclophosphamide
Cisplatin
Survival Rate
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals : A Southwest Oncology Group pilot study. / Taylor, Charles W.; Crowley, John; Williamson, Stephen K.; Miller, Thomas P; Taylor, Sarah A.; Giri, T. G Shanker; Stephens, Ronald L.; Livingston, Robert B.

In: Journal of Clinical Oncology, Vol. 8, No. 11, 11.1990, p. 1811-1817.

Research output: Contribution to journalArticle

Taylor, Charles W. ; Crowley, John ; Williamson, Stephen K. ; Miller, Thomas P ; Taylor, Sarah A. ; Giri, T. G Shanker ; Stephens, Ronald L. ; Livingston, Robert B. / Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals : A Southwest Oncology Group pilot study. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 11. pp. 1811-1817.
@article{cf6a40c59b414628b17c9d78f3e6580c,
title = "Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group pilot study",
abstract = "We designed an intensive, weekly treatment regimen for patients with small-cell lung cancer (SCLC) using six of the most active chemotherapeutic agents for this disease (doxorubicin [DOX], cyclophosphamide [CTX], vincristine [VCR], etoposide [VP-16], cisplatin [CDDP], and methotrexate [MTX]). The goal of this program was to gain rapid, repetitive exposure to multiple, active drugs. Treatment was administered weekly for a total of 16 weeks. Seventy-six SCLC patients (limited disease, 34; extensive disease, 42) were treated. The overall complete plus partial response rate was 82{\%}. Complete response rates of 47{\%} and 38{\%} were observed in patients with limited (LD) and extensive disease (ED), respectively. The median survivals for patients with LD and ED were 16.6 and 11.4 months, respectively. Toxicities were tolerable and were primarily hematologic. Twenty-six patients had one or more transient life-threatening toxicities, but only one patient developed a fatal toxicity. Eighty-four percent of the patients received 80{\%} or greater of the intended protocol dosages over the entire 16-week treatment period. We conclude that this intensive, short-duration treatment regimen is at least as good as other {"}standard{"} regimens, and we are encouraged by the complete response rate and median survival in patients with ED SCLC.",
author = "Taylor, {Charles W.} and John Crowley and Williamson, {Stephen K.} and Miller, {Thomas P} and Taylor, {Sarah A.} and Giri, {T. G Shanker} and Stephens, {Ronald L.} and Livingston, {Robert B}",
year = "1990",
month = "11",
language = "English (US)",
volume = "8",
pages = "1811--1817",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals

T2 - A Southwest Oncology Group pilot study

AU - Taylor, Charles W.

AU - Crowley, John

AU - Williamson, Stephen K.

AU - Miller, Thomas P

AU - Taylor, Sarah A.

AU - Giri, T. G Shanker

AU - Stephens, Ronald L.

AU - Livingston, Robert B

PY - 1990/11

Y1 - 1990/11

N2 - We designed an intensive, weekly treatment regimen for patients with small-cell lung cancer (SCLC) using six of the most active chemotherapeutic agents for this disease (doxorubicin [DOX], cyclophosphamide [CTX], vincristine [VCR], etoposide [VP-16], cisplatin [CDDP], and methotrexate [MTX]). The goal of this program was to gain rapid, repetitive exposure to multiple, active drugs. Treatment was administered weekly for a total of 16 weeks. Seventy-six SCLC patients (limited disease, 34; extensive disease, 42) were treated. The overall complete plus partial response rate was 82%. Complete response rates of 47% and 38% were observed in patients with limited (LD) and extensive disease (ED), respectively. The median survivals for patients with LD and ED were 16.6 and 11.4 months, respectively. Toxicities were tolerable and were primarily hematologic. Twenty-six patients had one or more transient life-threatening toxicities, but only one patient developed a fatal toxicity. Eighty-four percent of the patients received 80% or greater of the intended protocol dosages over the entire 16-week treatment period. We conclude that this intensive, short-duration treatment regimen is at least as good as other "standard" regimens, and we are encouraged by the complete response rate and median survival in patients with ED SCLC.

AB - We designed an intensive, weekly treatment regimen for patients with small-cell lung cancer (SCLC) using six of the most active chemotherapeutic agents for this disease (doxorubicin [DOX], cyclophosphamide [CTX], vincristine [VCR], etoposide [VP-16], cisplatin [CDDP], and methotrexate [MTX]). The goal of this program was to gain rapid, repetitive exposure to multiple, active drugs. Treatment was administered weekly for a total of 16 weeks. Seventy-six SCLC patients (limited disease, 34; extensive disease, 42) were treated. The overall complete plus partial response rate was 82%. Complete response rates of 47% and 38% were observed in patients with limited (LD) and extensive disease (ED), respectively. The median survivals for patients with LD and ED were 16.6 and 11.4 months, respectively. Toxicities were tolerable and were primarily hematologic. Twenty-six patients had one or more transient life-threatening toxicities, but only one patient developed a fatal toxicity. Eighty-four percent of the patients received 80% or greater of the intended protocol dosages over the entire 16-week treatment period. We conclude that this intensive, short-duration treatment regimen is at least as good as other "standard" regimens, and we are encouraged by the complete response rate and median survival in patients with ED SCLC.

UR - http://www.scopus.com/inward/record.url?scp=0025155530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025155530&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 1811

EP - 1817

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -